argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 41.72B +23.6% |
| Revenue (ttm) | 4.11B +79.4% |
| Net Income | 1.29B +39.9% |
| EPS | 19.51 +41.1% |
| Shares Out | 62.19M |
| PE Ratio | 34.39 |
| Forward PE | 25.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,808 |
| Average Volume | 85,474 |
| Open | 692.60 |
| Previous Close | 670.80 |
| Day's Range | 678.60 - 702.00 |
| 52-Week Range | 456.60 - 810.00 |
| Beta | -0.06 |
| RSI | 56.73 |
| Earnings Date | May 7, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
Argenx price target raised to $1,016 from $1,013 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Argenx (ARGX) to $1,016 from $1,013 and keeps a Buy rating on the shares. Approval of Vyvgart and Vyvgart Hytrulo…
Argenx Wins FDA Nod Expanding VYVGART Label To All Adult GMG Patients
(RTTNews) - argenx SE (ARGX) announced that the U.S. FDA has approved a label expansion for VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the trea...
argenx (ARGX) Receives FDA Approval for Expanded Vyvgart Label in Myasthenia Gravis
argenx (ARGX) Receives FDA Approval for Expanded Vyvgart Label in Myasthenia Gravis
Argenx (ARGX) Gains FDA Approval for Expanded Vyvgart Use
Argenx (ARGX) Gains FDA Approval for Expanded Vyvgart Use
Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
Argenx (ARGX) announced the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The approved supplemental Biolog...
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and tr...
ARGX Maintained by Guggenheim -- Price Target Raised to $1135
ARGX Maintained by Guggenheim -- Price Target Raised to $1135
ARGX Maintained by Wells Fargo -- Price Target Raised to $1260
ARGX Maintained by Wells Fargo -- Price Target Raised to $1260
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Argenx (ARGX) to $1,170 from $1,230 and keeps an Overweight rating on the shares.
Argenx price target raised to $1,135 from $1,120 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Argenx (ARGX) to $1,135 from $1,120 and keeps a Buy rating on the shares. The firm adjusted estimates following the
Argenx price target raised to $1,260 from $1,247 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,260 from $1,247 and keeps an Overweight rating on the shares. The firm says Vyvgart’s growth remains durable with
Argenx price target lowered to $1,222 from $1,227 at Stifel
Stifel lowered the firm’s price target on Argenx (ARGX) to $1,222 from $1,227 and keeps a Buy rating on the shares following an in-line Q1 report. Despite seasonality headwinds, management
Argenx Obliterates Profit Expectations On 'Solid Print' For Its Immunology Powerhouse
Argenx stock rose early Thursday on better-than-expected first-quarter profit, though sales missed some forecasts.
argenx SE Earnings Call Transcript: Q1 2026
Q1 2026 saw 63% revenue growth and strong operating leverage, with VYVGART leading in MG and CIDP and multiple label expansions and pipeline catalysts ahead. Vision 2030 remains the strategic focus, supported by robust cash and continued investment in innovation.
argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer
Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of peo...
Pre-Market Earnings Report for May 7, 2026 : MCD, CNQ, HWM, SRE, LNG, TRGP, VST, GWW, ARGX, DDOG, ZTS, SHEL
The following companies are expected to report earnings prior to market open on 05/07/2026. Visit our Earnings Calendar for a full list of expected earnings releases.McDonald's Corporation (MCD)is rep...
argenx SE (XBRU:ARGX) Q1 2026: Everything You Need To Know Ahead Of Earnings
argenx SE (XBRU:ARGX) Q1 2026: Everything You Need To Know Ahead Of Earnings
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today an...
Noteworthy ETF Outflows: IBB, REGN, ARGX, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Biotechnology ETF (Symbol: IBB) where we have detected an appr...
argenx (ARGX) Reveals New Vyvgart Data at 2026 AAN Annual Meeting
argenx (ARGX) Reveals New Vyvgart Data at 2026 AAN Annual Meeting
Argenx announces Phase 3 Adapt Oculus study met primary endpoint
argenx (ARGX) announced the presentation of new data for Vyvgart in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy at the 2026 American Academy of Neurology, AAN, Annual Meeti...
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, O...
Wedbush Reaffirms ARGX, NUVB, FENC At Outperform; Lifts PT For Kiniksa; Keeps NVCR At Neutral
(RTTNews) - The biotech sector has always been a space where science, capital, and sentiment intersect in complex ways. From cautious optimism around breakthrough therapies to concerns over valuation ...
Oppenheimer Lowers Price Target for ARGX, Reiterates Outperform Rating | ARGX Stock News
Oppenheimer Lowers Price Target for ARGX, Reiterates Outperform Rating | ARGX Stock News